Direct Compression Constraints for a Multi-Component Botanical Extract Powder

The Qingwen Zhili Powder Veterinary Grade API (QZP API) entering tablet processing is a multi-component botanical extract powder with residual moisture measured by Karl Fischer titration generally controlled between 3.0% and 6.0% w/w. When moisture exceeds 6.0% w/w and die temperature exceeds 40°C, upper-punch sticking and edge picking are observed on a 16-station rotary press at turret speeds above 45 rpm because the extract matrix enters a rubbery viscoelastic state. Direct compression is limited to formulations with API loading not exceeding 15% w/w, where microcrystalline cellulose at 40-55% w/w and lactose monohydrate at 25-40% w/w provide plastic deformation; crospovidone at 2.0-4.0% w/w is used as disintegrant, and colloidal silicon dioxide at 0.5-1.0% w/w reduces hopper arching. Precompression force of 3-6 kN followed by main compression at 15-25 kN is applied to expel interstitial air and prevent capping. Tablets are compressed to hardness 60-80 N measured with a tablet hardness tester at a load rate of 10 N/s and thickness variation within ±5% of target; friability is tested per USP <1216> and must remain below 1.0%, while disintegration is tested per USP <701> in distilled water at 37°C ± 0.5°C. When wet granulation is selected, the API is blended with 60% of the filler fraction, then massed with 5.0% w/v povidone K30 in purified water; the wet mass is dried in a fluid-bed dryer at inlet air temperature 55-65°C until loss on drying reaches 2.0-3.5%. The terminal tablet is film-coated using an aqueous HPMC 6 cP dispersion at atomization pressure 1.5-2.5 bar and bed temperature 40-45°C to limit moisture ingress. Release testing under 21 CFR 211.166 includes assay, impurity profile, dissolution, and moisture; batch-to-batch bulk density variation from 0.38 g/mL to 0.58 g/mL requires feeder recalibration at every lot change.

What Changes When a Multi-Component Botanical API Is Processed into a Sterile Veterinary Injection?

For sterile injectable processing, the QZP API must be dissolved in Water for Injection of EP or USP grade at 20-25°C under nitrogen blanketing. The concentrated solution is prefiltered through a 0.45 µm PVDF membrane, then sterile-filtered through a 0.22 µm PES membrane with bacterial retention validation per ASTM F838-20. Filtration capacity should not exceed 0.5 L/min per 0.6 m² of membrane area to prevent premature fouling from colloidal extract fractions. Aseptic filling is conducted in an ISO 14644-1 Class 5 zone with Grade A air supply; if terminal steam sterilization at 121°C for 15 min is intended, previous forced degradation must confirm marker compound recovery, and published data for this specific API configuration is limited. The solution is adjusted to 280-320 mOsm/kg with sodium chloride at 0.85-0.90% w/v, and pH is maintained between 6.0 and 7.5 with citrate or phosphate buffer. Sub-visible particle testing per USP <788> light obscuration method requires no more than 6,000 particles ≥10 µm and no more than 600 particles ≥25 µm per container for products ≤100 mL. Bacterial endotoxin testing per USP <85> is set from the maximum administered dose; a common release limit used in veterinary parenteral development is ≤2.5 EU/mg of API. Sterility testing per USP <71> membrane filtration is performed on 20 filled containers from each sterilization load.

Operational boundaries include avoidance of acidification below pH 4.5, because polyphenol-rich extract fractions can form insoluble aggregates; the exact precipitation boundary for each API lot is confirmed by phase-solubility screening at 25°C. If dissolved oxygen exceeds 2.0 mg/L, sodium metabisulfite at 0.05-0.1% w/v is added to protect oxygen-sensitive constituents. Terminal container closure is Type I glass vials of 10 mL or 50 mL sealed with chlorobutyl rubber stoppers and aluminum caps; filled vials are inspected for container integrity using vacuum decay at 0.3 bar differential. The process is not suitable for direct use of unfractionated extract powder without depyrogenation and bioburden reduction because the initial total aerobic microbial count may exceed 10² CFU/g, requiring pre-treatment through activated carbon or tangential-flow filtration before sterile filtration.

Capsule Fill Weight Control and Extract Granule Flow Limits

Because native QZP API powder has poor flow and low bulk density, capsule filling is conventionally performed after dry granulation or slugging. A direct-fill capsule formulation may contain 15-30% w/w API, 55-75% w/w lactose monohydrate or mannitol, 5-10% w/w microcrystalline cellulose, 0.5-1.0% w/w magnesium stearate, and 0.5% w/w colloidal silicon dioxide. The blend is mixed in a bin blender at 75% fill volume for 15-20 min; mixing beyond 25 min at 25 rpm increases electrostatic charging when ambient relative humidity is below 30%. Capsule fill weight is targeted for relative standard deviation no greater than 3.0% across 20 successive filled capsules. A tamping-pin capsule filler with pin penetration depth of 8-12 mm and compression force 10-15 N is used for size 0 or 1 HPMC capsules. Release dissolution is conducted per USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M HCl at 37°C ± 0.5°C; the product-specific Q value must be established during development, and an 80% release at 45 min is used only as a comparative development target. Hard HPMC capsules are preferred over gelatin to reduce shell cross-linking under high humidity; stability is evaluated at 45°C/75% RH for 3 months per 21 CFR 211.166. If API residual moisture exceeds 4.5% w/w, the formulation is dry-granulated with 0.5% magnesium stearate to prevent picking in the capsule dosator.

For oral powder sachets and drinking-water reconstitution, the API is dry-mixed with a water-soluble carrier such as dextrose monohydrate or lactose monohydrate at a ratio of 1:10 to 1:199, depending on the labeled dose per sachet. The mixing operation is carried out in a 500 L ribbon blender at 30-50 rpm for 10-15 min; pre-blending the API with an equal weight of carrier for 5 min before main mixing reduces assay relative standard deviation to below 5%. The final powder is filled into 100 g or 1 kg foil laminate sachets under ambient relative humidity ≤40%. Non-sterile oral powder release follows Ph. Eur. 5.1.4 acceptance criteria: total aerobic microbial count ≤10³ CFU/g, total yeast and mold count ≤10² CFU/g, and absence of Escherichia coli per 1 g. Moisture content determined by Karl Fischer titration per USP <921> Method Ia is controlled at ≤6.0% w/w. Sieve analysis using 63 µm and 500 µm stainless steel sieves controls the particle size distribution so that at least 90% of the dry blend passes the 500 µm screen and fines below 63 µm remain ≤15% w/w. For drinking-water administration via siphon dosing, complete wetting must occur within 5 min under 100 rpm stirring at 25°C, with undispersed residue less than 0.1% w/w on a 75 µm screen. Acidulants such as anhydrous citric acid are not used as sole carriers because acidic hydrolysis of the extract matrix can reduce marker compound recovery during storage.

When Fluid-Bed Granulation Is Preferred Over High-Shear Mixing for Extract-Based API

When the API lot bulk density falls below 0.45 g/mL and Carr’s index exceeds 30%, fluid-bed top-spray granulation is preferred over high-shear mixing because high-shear granulation at impeller speeds above 250 rpm can cause resinous adhesion to the bowl wall. The API is blended with 60-75% w/w sucrose or maltodextrin, 1.0-2.0% w/w povidone K30 as a 5% w/v aqueous binder solution, and 0.5% w/w sodium chloride as a palatability agent. In a top-spray fluid-bed granulator, inlet air temperature is maintained at 55-70°C, product temperature at 32-38°C, spray rate at 8-20 g/min per kg batch, and atomization air pressure at 1.5-3.0 bar. Granulation endpoint is reached when granule size distribution is 0.2-0.8 mm and fines below 75 µm do not exceed 10% w/w. Dried granules are milled through a 1.0 mm screen and filled into aluminum foil pouches. Release testing for non-sterile granules includes loss on drying at 2.0-3.5% and microbial limits per Ph. Eur. 5.1.4. Uniformity of mass for single-dose granules is tested per Ph. Eur. 2.9.5 using 20 units. Drying below 2.0% produces excessive friability and dusting; drying above 3.5% causes block lumping in the pouch and loss of flow during sachet filling.

In medicated feed premix manufacturing, the QZP API is usually incorporated at 0.5-5.0% w/w into a corncob meal or calcium carbonate carrier for feed mills; the exact ratio is derived from the target in-feed dose and cross-contamination limits in EU Regulation 2019/4. Mixing is performed in a 1.0 m³ horizontal ribbon blender at 40 rpm for 12 min, which gives a 10-sample assay relative standard deviation ≤5.0% when the API is pre-sieved through a 250 µm screen before charging. Extending mixing beyond 20 min reduces homogeneity because the carrier temperature increases and static charge causes API migration to the vessel surface. The terminal premix is filled into 25 kg paper bags with a polyethylene liner; residual moisture is controlled at ≤10% w/w. The carrier is tested for aflatoxin B1 content below 20 µg/kg per EU Directive 2002/32/EC. Homogeneity and cross-contamination documentation follow EU Regulation 2019/4 Annex II, with a carry-over limit into non-target feed set below 1% of the lowest active concentration unless residue data support a lower value. Alkaline mineral carriers such as limestone above 20% w/w are avoided because a high local pH can destabilize extract marker compounds during storage.

When the API is reconstituted as a liquid drinking-water formulation, the dominant process risk shifts from blend homogeneity to chemical stability in aqueous media. The API is dissolved in a stainless steel 316L mixing vessel at 25-35°C with a propeller impeller at 200-300 rpm; pre-wetting in 10% of the final water volume before dilution to final volume reduces lump formation. The solution is buffered with citrate buffer to pH 6.0-7.5 and preserved with 0.1% w/v methylparaben and 0.02% w/v propylparaben. Sodium metabisulfite at 0.05-0.1% w/v is added when dissolved oxygen exceeds 2.0 mg/L, and softened water with hardness below 20 mg/L CaCO3 is used to prevent complexation between extract polyphenols and divalent cations. The solution is filtered through 0.45 µm cartridge filters, filled into amber polyethylene terephthalate containers of 1 L or 5 L, and sealed for dosing pump use. Antimicrobial effectiveness testing per Ph. Eur. 5.1.3 and chemical stability under 25°C/60% RH for 24 months are required. Light exposure is controlled by amber primary packaging because UV irradiation can reduce marker compound recovery in aqueous solution. Unpreserved working dilutions at the farm should be replaced within 24 hours when the diluted product reaches 25°C.